Theragen Etex Co.,Ltd.

KOSDAQ:A066700 Voorraadrapport

Marktkapitalisatie: ₩108.0b

Theragen EtexLtd Inkomsten in het verleden

Verleden criteriumcontroles 4/6

Theragen EtexLtd has been growing earnings at an average annual rate of 1.5%, while the Pharmaceuticals industry saw earnings growing at 11.7% annually. Revenues have been growing at an average rate of 12.4% per year. Theragen EtexLtd's return on equity is 16.4%, and it has net margins of 11.3%.

Belangrijke informatie

1.5%

Groei van de winst

0.07%

Groei van de winst per aandeel

Pharmaceuticals Groei van de industrie11.3%
Inkomstengroei12.4%
Rendement op eigen vermogen16.4%
Nettomarge11.3%
Laatste winstupdate30 Jun 2024

Recente prestatie-updates uit het verleden

Recent updates

Lacklustre Performance Is Driving Theragen Etex Co.,Ltd.'s (KOSDAQ:066700) Low P/E

Oct 17
Lacklustre Performance Is Driving Theragen Etex Co.,Ltd.'s (KOSDAQ:066700) Low P/E

Estimating The Fair Value Of Theragen Etex Co.,Ltd. (KOSDAQ:066700)

Aug 07
Estimating The Fair Value Of Theragen Etex Co.,Ltd. (KOSDAQ:066700)

Theragen EtexLtd's (KOSDAQ:066700) Solid Profits Have Weak Fundamentals

Mar 27
Theragen EtexLtd's (KOSDAQ:066700) Solid Profits Have Weak Fundamentals

Calculating The Intrinsic Value Of Theragen Etex Co.,Ltd. (KOSDAQ:066700)

Mar 21
Calculating The Intrinsic Value Of Theragen Etex Co.,Ltd. (KOSDAQ:066700)

Is Theragen EtexLtd (KOSDAQ:066700) A Risky Investment?

Feb 11
Is Theragen EtexLtd (KOSDAQ:066700) A Risky Investment?

Did Theragen EtexLtd's (KOSDAQ:066700) Share Price Deserve to Gain 36%?

Jan 16
Did Theragen EtexLtd's (KOSDAQ:066700) Share Price Deserve to Gain 36%?

A Look At The Intrinsic Value Of Theragen Etex Co.,Ltd. (KOSDAQ:066700)

Dec 21
A Look At The Intrinsic Value Of Theragen Etex Co.,Ltd. (KOSDAQ:066700)

We're Not So Sure You Should Rely on Theragen EtexLtd's (KOSDAQ:066700) Statutory Earnings

Nov 23
We're Not So Sure You Should Rely on Theragen EtexLtd's (KOSDAQ:066700) Statutory Earnings

Opbrengsten en kosten

Hoe Theragen EtexLtd geld verdient en uitgeeft. Gebaseerd op laatst gerapporteerde winst, op LTM-basis.


Inkomsten en omzetgeschiedenis

KOSDAQ:A066700 Opbrengsten, kosten en inkomsten (KRW Millions )
DatumInkomstenInkomstenG+A UitgavenR&D-uitgaven
30 Jun 24241,94627,40196,4525,342
31 Mar 24231,95427,48789,9145,042
31 Dec 23221,72527,77483,1234,672
30 Sep 23209,6044,81776,8395,125
30 Jun 23201,8585,59768,2474,767
31 Mar 23193,9837,24861,2665,097
31 Dec 22190,76911,03858,2665,038
30 Sep 22186,8887,85460,5695,133
30 Jun 22181,746-1,42963,4925,656
31 Mar 22176,380-5,70063,7535,986
31 Dec 21166,567-11,85460,2516,515
30 Sep 21158,350-9,01255,4426,867
30 Jun 21154,033-5,94752,6067,072
31 Mar 21147,518-9,59549,5886,797
31 Dec 20143,023-8,96844,9096,418
30 Sep 20141,70133,34536,4045,628
30 Jun 20137,21634,49632,0324,732
31 Mar 20140,55344,76029,1154,340
31 Dec 19138,08343,64628,8484,099
30 Sep 19137,076-3,21828,5354,157
30 Jun 19133,374-6,19827,8784,345
31 Mar 19121,750-10,33427,8214,207
31 Dec 18117,475-10,21827,7944,171
30 Sep 18112,293-48826,5035,098
30 Jun 18108,9141,65027,3144,543
31 Mar 18110,58574328,1873,545
31 Dec 17107,5921,27428,2883,366
30 Sep 17107,268-1,61729,7042,506
30 Jun 17103,572-15428,3522,838
31 Mar 1799,38453426,1633,806
31 Dec 16101,2832,04325,2283,944
30 Sep 1697,942-6,49527,1724,087
30 Jun 1699,460-6,82429,0383,768
31 Mar 16100,873-6,55030,4673,702
31 Dec 1598,884-6,80331,5243,632
30 Sep 1590,0063,66526,5703,231
30 Jun 1587,8103,97525,9173,350
31 Mar 1586,8311,93226,5443,070
31 Dec 1489,7431,47926,7983,079
30 Sep 1498,08272328,3073,834
30 Jun 1496,558-42126,7903,827
31 Mar 1496,7061,20825,1114,101
31 Dec 1390,7311,32723,3464,210

Kwaliteitswinsten: A066700 has a large one-off gain of ₩22.5B impacting its last 12 months of financial results to 30th June, 2024.

Groeiende winstmarge: A066700's current net profit margins (11.3%) are higher than last year (2.8%).


Analyse vrije kasstroom versus winst


Analyse van de winstgroei in het verleden

Winsttrend: A066700 has become profitable over the past 5 years, growing earnings by 1.5% per year.

Versnelling van de groei: A066700's earnings growth over the past year (389.6%) exceeds its 5-year average (1.5% per year).

Winst versus industrie: A066700 earnings growth over the past year (389.6%) exceeded the Pharmaceuticals industry 21.9%.


Rendement op eigen vermogen

Hoge ROE: A066700's Return on Equity (16.4%) is considered low.


Rendement op activa


Rendement op geïnvesteerd vermogen


Ontdek sterk presterende bedrijven uit het verleden